These findings highlight demographic factors' importance in UTI risk among T2DM patients on SGLT2 inhibitors.<h4>Conclusion</h4>The study identified varying risks of urinary tract infections (UTIs) among users of SGLT2 inhibitors, influenced by factors like gender, age, and existing health conditions. This evidence concerns the gene SLC5A2 and bacterial urinary tract infection.